KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.

doi:10.1136/jitc-2022-006530

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.

Journal for immunotherapy of cancer - 1 Feb 2023

Erbe Amy K, Diccianni Mitch B, Mody Rajen, Naranjo Arlene, Zhang Fan F, Birstler Jen, Kim KyungMann, Feils Arika S, Hung Jung-Tung, London Wendy B, Shulkin Barry L, Mathew Varsha, Parisi Marguerite T, Servaes Sabah, Asgharzadeh Shahab, Maris John M, Park Julie, Yu Alice L, Sondel Paul M, Bagatell Rochelle

Abstract excerpt

BACKGROUND: In the Children's Oncology Group ANBL1221 phase 2 trial for patients with first relapse/first declaration of refractory high-risk neuroblastoma, irinotecan and temozolomide (I/T) combined with either temsirolimus (TEMS) or immunotherapy (the anti-GD2 antibody dinutuximab (DIN) and granulocyte macrophage colony stimulating factory (GM-CSF)) was administered. The response rate among patients treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Granulocyte-Macrophage Colony-Stimulating Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histocompatibility Antigens

Share to Immunotherapy

Share to Irinotecan

Share to Leukocytes, Mononuclear

Share to Neuroblastoma

Share to Receptors, KIR

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 36822669
DOI: 10.1136/jitc-2022-006530
PMCID: PMC9950969

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.PMID 36822669Read ↗

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.Semantic proximity Read ↗

Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.Semantic proximity Read ↗

KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.Semantic proximity Read ↗

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survivalSemantic proximity Read ↗

Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion TrialSemantic proximity Read ↗

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity Read ↗

Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity Read ↗

Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trialSemantic proximity Read ↗

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.Semantic proximity Read ↗

Clinical Impact of KIR2DS3 and KIR2DL3 Genes in Neuroblastoma Patients.Semantic proximity Read ↗

GD2 targeting CAR T cells for neuroblastomaSemantic proximity Read ↗

Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.